All In Biotech

Drug Trial Radar · NCT07791186

Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years

A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
BMI KoreaIndustry
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2 Omicron JN .1 variant, in healthy adults aged 19 to 55 years. Participants will be enrolled sequentially into three ascending-dose cohorts and randomized within each cohort to receive a single intramuscular injection of BMI2012 or placebo. A sentinel dosing strategy with staggered administration will be used to monitor safety before enrollment of the remaining participants in each dose cohort. A Data Safety Monitoring Board (DSMB) will review safety data to determine whether enrollment may continue and to assess dose levels appropriate for further clinical development. The primary objective is to assess the safety and tolerability of BMI2012 across the dose levels studied. Secondary objectives include exploratory evaluation of humoral and cell-mediated immune responses to BMI2012 through 52 weeks after vaccination.

Conditions

  • Prevention of COVID-19 Variant (Omicron JN.1)

Interventions

  • BMI2012 low-doseBiological

    Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single low-dose intramuscular injection at Visit 2

  • Placebo low-doseOther

    Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 low-dose

  • BMI2012 mid-doseBiological

    Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single mid-dose intramuscular injection at Visit 2

  • Placebo mid-doseOther

    Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 mid-dose

  • BMI2012 high-doseBiological

    Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single high-dose intramuscular injection at Visit 2

  • Placebo high-doseOther

    Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 high-dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events Following Investigational Product AdministrationTime frame: From administration through Day 28

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hallym University Kangnam St.Heart Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Ajou University Medical Center

    Suwon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.